Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden.
Astellas Pharma GmbH, based in Munich, Germany, is the German subsidiary of the global Astellas Group, headed by Tokyo-based Astellas Pharma Inc. European headquarter is the Astellas Pharma Europe Ltd. („Astellas Pharma EMEA“) in London, UK.
Astellas is a research-driven pharmaceutical company committed to delivering innovative and proven medicines to improve the health and quality of life of people worldwide. In the field of research and development of novel drugs, Astellas focuses on the therapeutic areas of urology, oncology, immunology, nephrology and neuroscience. Astellas sees itself as a partner in healthcare, working day-to-day to add value to patients by providing and accessing innovative medicines.
Further information on the Astellas Group can be found on the Internet at www.astellas.com and www.astellas.de. Information on transplantation can be found at https://www.leben-mit-transplantation.de. Astellas supports continuing medical education https://fortbildung.astellas-med.de.
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s lead program, tab-cel™ (tabelecleucel), is in Phase 3 development for patients with Epstein-Barr virus associated post-transplant lymphoma, as well as other EBV associated cancers and autoimmune diseases including multiple sclerosis (MS). The company was founded in 2012 and is publicly traded on Nasdaq (symbol ATRA). Headquartered in South San Francisco, we have chosen Zug to establish our first European location.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.
Dr. Falk Pharma GmbH
Shire is one of the world’s leading biotechnology companies dedicated to treating patients with rare and complex diseases. We strive to develop breakthrough therapies for rare diseases in various medical specialties; based on our broad know-how and experience in complex diseases. For us, the patients and their needs come first.